QuidelOrtho (NASDAQ:QDEL) Surprises With Q2 CY2026 Sales But Stock Drops 21.6%
QuidelOrtho (NASDAQ: QDEL) reported Q2 CY2026 revenue of $630.9 million, up 2.8% year on year and above analysts’ estimates, and non-GAAP EPS of $0.13, above consensus. Full-year revenue guidance was $2.56 billion at the midpoint, 5.4% below estimates. The stock fell 21.6% to $12.80 after results, citing China demand headwinds.
How this was made
The 30-second read
Why it matters
Investors appear to have repriced QDEL primarily on full-year revenue guidance coming in below analysts’ estimates, alongside evidence of profitability deterioration (adjusted operating margin negative in Q2) and stated China demand headwinds.
Market read
A guidance miss versus consensus, despite a Q2 revenue and EPS beat, triggered a large immediate drawdown, making the forward outlook the key trading variable.
What to watch
The article notes margin contraction and expense growth outpacing revenue, but does not quantify segment-level drivers beyond China, leaving uncertainty around whether the guidance miss is structural or cyclical.
Background
QuidelOrtho, formed from the 2022 Quidel and Ortho Clinical Diagnostics merger, sells diagnostic testing solutions across point-of-care and lab instruments.
Ticker impact
QuidelOrtho reported Q2 CY2026 sales of $630.9M (+2.8% YoY) but guided full-year revenue to $2.56B, 5.4% below estimates, and shares fell 21.6%.
Bearish near-term bias, with follow-through risk if investors focus on the guidance gap and China/respiratory headwinds.
The article provides a concrete guidance miss versus consensus plus a large same-day drop (21.6%), and cites ongoing China demand headwinds and margin contraction (negative 3.5% adjusted operating margin in Q2).
Market effects
Signals continued pressure in IVD/respiratory diagnostics demand and sensitivity to pricing/regulatory guidance, which can weigh on peer sentiment.
China-specific demand headwinds tied to proposed IVD pricing guidelines may keep regional diagnostics demand cautious.
Highlights how guidance gaps can dominate even when quarterly revenue and EPS beat, reinforcing valuation sensitivity across healthcare diagnostics.
Counterpoint
The quarter showed underlying strength with revenue and non-GAAP EPS beating estimates, suggesting the guidance miss could be temporary if China stabilizes.
Key entities
- companyQuidelOrtho
Healthcare diagnostics company reporting Q2 CY2026 results and full-year guidance; shares dropped 21.6% after the release.
- executiveBrian J. Blaser
CEO who attributed China demand headwinds to proposed IVD pricing guidelines and a softer global respiratory environment.
